Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

Jean D. Boyer; Michael A. Chattergoon; Kenneth E. Ugen; Ami Shah; Mosi Bennett; Adam Cohen; Susan Nyland; Kim E. Lacy; Mark L. Bagarazzi; Terry J. Higgins; Yaela Baine; Richard B. Ciccarelli; Richard S. Ginsberg; Rob Roy MacGregor; David B. Weiner

doi:10.1006/clim.1998.4616

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

Jean D. Boyer, Michael A. Chattergoon, Kenneth E. Ugen, Ami Shah, Mosi Bennett, Adam Cohen, Susan Nyland, Kim E. Lacy, Mark L. Bagarazzi, Terry J. Higgins, Yaela Baine, Richard B. Ciccarelli, Richard S. Ginsberg, Rob Roy MacGregor, David B. Weiner

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Abstract

A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.

Original language	English (US)
Pages (from-to)	100-107
Number of pages	8
Journal	Clinical Immunology
Volume	90
Issue number	1
DOIs	https://doi.org/10.1006/clim.1998.4616
State	Published - Jan 1999
Externally published	Yes

Keywords

DNA vaccines
HIV-1
Immunotherapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1006/clim.1998.4616

Cite this

Boyer, J. D., Chattergoon, M. A., Ugen, K. E., Shah, A., Bennett, M., Cohen, A., Nyland, S., Lacy, K. E., Bagarazzi, M. L., Higgins, T. J., Baine, Y., Ciccarelli, R. B., Ginsberg, R. S., MacGregor, R. R., & Weiner, D. B. (1999). Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clinical Immunology, 90(1), 100-107. https://doi.org/10.1006/clim.1998.4616

Boyer, JD, Chattergoon, MA, Ugen, KE, Shah, A, Bennett, M, Cohen, A, Nyland, S, Lacy, KE, Bagarazzi, ML, Higgins, TJ, Baine, Y, Ciccarelli, RB, Ginsberg, RS, MacGregor, RR & Weiner, DB 1999, 'Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial', Clinical Immunology, vol. 90, no. 1, pp. 100-107. https://doi.org/10.1006/clim.1998.4616

@article{5bf7b90495224b75a4196c1eb7dfaeea,

title = "Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial",

abstract = "A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.",

keywords = "DNA vaccines, HIV-1, Immunotherapy",

author = "Boyer, {Jean D.} and Chattergoon, {Michael A.} and Ugen, {Kenneth E.} and Ami Shah and Mosi Bennett and Adam Cohen and Susan Nyland and Lacy, {Kim E.} and Bagarazzi, {Mark L.} and Higgins, {Terry J.} and Yaela Baine and Ciccarelli, {Richard B.} and Ginsberg, {Richard S.} and MacGregor, {Rob Roy} and Weiner, {David B.}",

note = "Funding Information: The authors thank the staff of the University of Pennsylvania General Clinical Research Center for their help with the vaccinees. We acknowledge the group at WLVP, Inc. for manufacturing the vaccine used in the study. We are particularly grateful to the vaccinees for their willingness to give of their time and efforts throughout the conduct of the study. We are grateful to the AIDS Reagent and Reference Repository for the recombinant vaccinia vectors. This work was supported in part by NIH SPIRAT and Vaccine grants.",

year = "1999",

month = jan,

doi = "10.1006/clim.1998.4616",

language = "English (US)",

volume = "90",

pages = "100--107",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Enhancement of cellular immune response in HIV-1 seropositive individuals

T2 - A DNA-based trial

AU - Boyer, Jean D.

AU - Chattergoon, Michael A.

AU - Ugen, Kenneth E.

AU - Shah, Ami

AU - Bennett, Mosi

AU - Cohen, Adam

AU - Nyland, Susan

AU - Lacy, Kim E.

AU - Bagarazzi, Mark L.

AU - Higgins, Terry J.

AU - Baine, Yaela

AU - Ciccarelli, Richard B.

AU - Ginsberg, Richard S.

AU - MacGregor, Rob Roy

AU - Weiner, David B.

N1 - Funding Information: The authors thank the staff of the University of Pennsylvania General Clinical Research Center for their help with the vaccinees. We acknowledge the group at WLVP, Inc. for manufacturing the vaccine used in the study. We are particularly grateful to the vaccinees for their willingness to give of their time and efforts throughout the conduct of the study. We are grateful to the AIDS Reagent and Reference Repository for the recombinant vaccinia vectors. This work was supported in part by NIH SPIRAT and Vaccine grants.

PY - 1999/1

Y1 - 1999/1

N2 - A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.

AB - A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.

KW - DNA vaccines

KW - HIV-1

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0032937060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032937060&partnerID=8YFLogxK

U2 - 10.1006/clim.1998.4616

DO - 10.1006/clim.1998.4616

M3 - Article

C2 - 9884357

AN - SCOPUS:0032937060

SN - 1521-6616

VL - 90

SP - 100

EP - 107

JO - Clinical Immunology

JF - Clinical Immunology

IS - 1

ER -

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this